ProMIS NeurosciencesPMN -0.45%32 Buyback Yield % is -58.54 as of Jul. 05, 2026. GuruFocus rates PMN with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 744 Biotechnology companies, ProMIS Neurosciences ranks worse than 84.95% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
ProMIS Neurosciences Buyback Yield % Related Terms
ProMIS Neurosciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMN vs BMEA, ANIX, ATRA: Buyback Yield % Comparison
For the Biotechnology subindustry, ProMIS Neurosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences (PMN) has a Buyback Yield % of -58.54 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #632 out of 744 companies in the Biotechnology industry, placing it in the top 84.9%.
Is ProMIS Neurosciences' Buyback Yield % too high?
ProMIS Neurosciences' current Buyback Yield % is -58.54. Based on the distribution chart, ProMIS Neurosciences ranks #632 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Buyback Yield % compare to BMEA and ANIX?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #632 out of 744 companies for Buyback Yield %. This places ProMIS Neurosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Buyback Yield % is -58.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Buyback Yield % of -58.54. The current Buyback Yield % is -58.54. ProMIS Neurosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Buyback Yield % is -58.54 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
32GF Score
Get the complete analysis for PMN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
